Ebola vaccine sat on the shelf ready to test for a decade

Almost a decade ago, scientists from Canada and the United States reported that they had created a vaccine that was 100 percent effective in protecting monkeys against the Ebola virus. The results were published in a respected journal, and health officials called them exciting. The researchers said tests in people might start within two years, and a product could potentially be ready for licensing by 2010 or 2011.

It never happened. The vaccine sat on a shelf. Only now is it undergoing the most basic safety tests in humans — with nearly 5,000 people dead from Ebola and an epidemic raging out of control in West Africa.

Its development stalled in part because Ebola is rare, and until now, outbreaks had infected only a few hundred people at a time. But experts also acknowledge that the absence of follow-up on such a promising candidate reflects a broader failure to produce medicines and vaccines for diseases that afflict poor countries. Most drug companies have resisted spending the enormous sums needed to develop products useful mostly to countries with little ability to pay…

The NY TIMES doesn’t need to waste space on defending the greed of corporate pharmaceutical giants. That’s what Congress is for.

Now, as the growing epidemic devastates West Africa and is seen as a potential threat to other regions as well, governments and aid groups have begun to open their wallets. A flurry of research to test drugs and vaccines is underway, with studies starting for several candidates, including the vaccine produced nearly a decade ago.

A federal official said in an interview on Thursday that two large studies involving thousands of patients were planned to begin soon in West Africa, and were expected to be described in detail on Friday by the World Health Organization.

With no vaccines or proven drugs available, the stepped-up efforts are a desperate measure to stop a disease that has defied traditional means of containing it.

Kind of like white folks noticing we don’t live in a post-racial society regardless of what Republicans say. The TIMES notices what anyone who cares about public health has always known. If it can make a bunch of money, any illness can receive study and attempts at a cure from the medical-industrial complex. The rest can waste their energy on hope.

Thanks, Mike

3 thoughts on “Ebola vaccine sat on the shelf ready to test for a decade

  1. PPE says:

    “…Despite its ferocity in humans, Ebola is a life-form of mysterious simplicity. A particle of Ebola is made of only six structural proteins, locked together to become an object that resembles a strand of cooked spaghetti. An Ebola particle is only around eighty nanometres wide and a thousand nanometres long. If it were the size of a piece of spaghetti, then a human hair would be about twelve feet in diameter and would resemble the trunk of a giant redwood tree.”
    “Inside the Ebola Wars” http://www.newyorker.com/magazine/2014/10/27/ebola-wars

  2. Tax$@work says:

    “Antiviral Compound Protects Nonhuman Primates Against Ebola Virus” (US Army Medical Research Institute of Infectious Diseases http://www.sciencenewsline.com/summary/2015021016340019.html ) Scientists protected 75 percent of rhesus monkeys infected with Ebola virus that were treated with a compound targeting the expression of VP24, a single Ebola virus protein–suggesting that VP24 may hold the key to developing effective therapies for the deadly disease. See also link to “Human Antibodies Produced in DNA-vaccinated Cows Protect in Lethal Models of Hantavirus”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.